This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Patard, J.-J. Articles by Belldegrun, A. S. Search for Related Content PubMed PubMed Citation Articles by Patard, J.-J. Articles by Belldegrun, A. S. Social Bookmarking                            What's this?

Use of the University of California Los Angeles Integrated Staging System to Predict Survival in Renal Cell Carcinoma: An International Multicenter Study

From the Department of Urology, Rennes University Hospital, Rennes; Department of Urology, CHU Henri Mondor, Créteil; Department of Urology, North Hospital, CHU of Saint Etienne, France; Department of Urology, David Geffen School of Medicine at University of California Los Angeles, CA; Department of Urology, University of Verona, Verona; Department of Urology, Medical School of University "Federico II," Naples, Italy; Department of Urology, The University of Texas M.D. Anderson Cancer Center, Houston, TX; Department of Urology, University Medical Center, Nijmegen, the Netherlands

Address reprint requests to Arie S. Belldegrun, MD, Department of Urology, David Geffen School of Medicine at the University of California Los Angeles, CHS 66-118, Box 951738, 10833 Le Conte Ave, Los Angeles, CA 90095-1738; e-mail: abelldegrun{at}mednet.ucla.edu

PURPOSE: To evaluate ability of the University of California Los Angeles Integrated Staging System (UISS) to stratify patients with localized and metastatic renal cell carcinoma (RCC) into risk groups in an international multicenter study.

PATIENTS AND METHODS: 4,202 patients from eight international academic centers were classified according to the UISS, which combines TNM stage, Fuhrman grade, and Eastern Cooperative Oncology Group performance status. Distribution of the UISS categories was assessed in the overall population and in each center.

RESULTS: The UISS stratified both localized and metastatic RCC into three different risk groups (P < .001). For localized RCC, the 5-year survival rates were 92%, 67%, and 44% for low-, intermediate-, and high-risk groups, respectively. A trend toward a higher risk of death was observed in all centers for increasing UISS risk category. For metastatic RCC, the 3-year survival rates were 37%, 23%, and 12% for low-, intermediate-, and high-risk groups, respectively; in 6 of 8 centers, a trend toward a higher risk of death was observed for increasing UISS risk category. A greater variability in survival rates among centers was observed for high-risk patients.

CONCLUSION: This study defines the general applicability of the UISS for predicting survival in patients with RCC. The UISS is an accurate predictor of survival for patients with localized RCC applicable to external databases. Although the UISS may be useful for patients with metastatic RCC, it may be less accurate in this subset of patients due to the heterogeneity of patients and treatments.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				T. Klatte, D. B. Seligson, J. LaRochelle, B. Shuch, J. W. Said, S. B. Riggs, N. Zomorodian, F. F. Kabbinavar, A. J. Pantuck, and A. S. Belldegrun Molecular Signatures of Localized Clear Cell Renal Cell Carcinoma to Predict Disease-Free Survival after Nephrectomy Cancer Epidemiol. Biomarkers Prev., March 1, 2009; 18(3): 894 - 900. [Abstract] [Full Text] [PDF]

				N. S. Vasudev, J. E. Brown, S. R. Brown, R. Rafiq, R. Morgan, P. M. Patel, D. O'Donnell, P. Harnden, M. Rogers, K. Cocks, et al. Prognostic Factors in Renal Cell Carcinoma: Association of Preoperative Sodium Concentration with Survival Clin. Cancer Res., March 15, 2008; 14(6): 1775 - 1781. [Abstract] [Full Text] [PDF]

				P. I. Karakiewicz, A. Briganti, F. K.-H. Chun, Q.-D. Trinh, P. Perrotte, V. Ficarra, L. Cindolo, A. De La Taille, J. Tostain, P. F.A. Mulders, et al. Multi-Institutional Validation of a New Renal Cancer-Specific Survival Nomogram J. Clin. Oncol., April 10, 2007; 25(11): 1316 - 1322. [Abstract] [Full Text] [PDF]

				J. S. Lam, A. Breda, A. S. Belldegrun, and R. A. Figlin Evolving Principles of Surgical Management and Prognostic Factors for Outcome in Renal Cell Carcinoma J. Clin. Oncol., December 10, 2006; 24(35): 5565 - 5575. [Abstract] [Full Text] [PDF]

				S. E. Eggener, O. Yossepowitch, J. A. Pettus, M. E. Snyder, R. J. Motzer, and P. Russo Renal Cell Carcinoma Recurrence After Nephrectomy for Localized Disease: Predicting Survival From Time of Recurrence J. Clin. Oncol., July 1, 2006; 24(19): 3101 - 3106. [Abstract] [Full Text] [PDF]

				H. T. Cohen and F. J. McGovern Renal-Cell Carcinoma N. Engl. J. Med., December 8, 2005; 353(23): 2477 - 2490. [Full Text] [PDF]